Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-324
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Administration
- Intravenous
01
Overview
ABBV-324 is an investigational drug being developed by AbbVie for the treatment of hepatocellular carcinoma (HCC) and squamous-cell non-small cell lung cancer (LUSC). It is currently being evaluated in clinical trials where it is administered intravenously, either as monotherapy or compared to lenvatinib. The primary aim of ongoing studies is to assess adverse events and changes in disease activity in adult participants with HCC or LUSC. The specific mechanism of action and molecular target for ABBV-324 have not been disclosed publicly as of now[1][2].
Beyond the preview
Go deeper on ABBV-324.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-324.